Eli Lilly (LLY) announced Thursday its obesity pill orforglipron delivered superior weight maintenance in a Phase 3 trial for obese or overweight adults who had previously received injectable weight loss drugs such as its Zepbound therapy or Novo’s (NVO) Wegovy.
Citing topline data from its ATTAIN-MAINTAIN trial, LLY said that patients who switched to orforglipron from Wegovy and Zepbound maintained their previously achieved weight loss with an average difference of 0.9 kg and 5.0 Kg, respectively, over 52 weeks.
The U.S.-based trial included adults with obesity or overweight with weight-related comorbidities who had initially undergone the highest doses of Wegovy or Zepbound for 72 weeks.
The study met the primary and all key secondary endpoints, and orforglipron indicated a safety and tolerability profile in line with data from prior Phase 3 studies for the once-daily pill, the Indiana-based drugmaker added.
This is a developing story. Check back for more updates.